3.25

2.52% +0.08

Leap Therapeutics Inc (LPTX)

Overview News Price History Option Chain Discussions Forecast Stock Split

Leap Therapeutics Inc stock is currently priced at $3.25, with a 24-hour trading volume of 403.13K. It has seen a +2.52% increased in the last 24 hours and a +31.05% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $3.19 pivot point. If it approaches the $3.27 resistance level, significant changes may occur.

Previous Close:

$3.17

Open:

$3.29

24h Volume:

403.13K

Market Cap:

$83.21M

Revenue:

$1.50M

Net Income/Loss:

$-81.41M

P/E Ratio:

-0.4992

EPS:

-6.51

Net Cash Flow:

$-43.75M

1W Performance:

+16.07%

1M Performance:

+31.05%

6M Performance:

+132.14%

1Y Performance:

+795.56%

1D Range:

$2.99

$3.39

52W Range:

$0.3536

$5.18

Leap Therapeutics Inc Stock (LPTX) Company Profile

Name

Leap Therapeutics Inc

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

617 714 0360

Address

47 Thorndike Street, Suite B1-1, Cambridge, MA

Employee

Twitter

@LeapTherapeutic

Next Earnings Date

2024-05-13

Latest SEC Filings

LPTX's Discussions on Twitter

Leap Therapeutics Inc Stock (LPTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-04-21	Initiated	Mizuho	Buy
Jun-04-21	Resumed	Robert W. Baird	Outperform
Jun-29-20	Initiated	Piper Sandler	Overweight
Feb-11-20	Initiated	Robert W. Baird	Outperform
Nov-15-19	Downgrade	Raymond James	Outperform → Mkt Perform
Sep-13-19	Resumed	Raymond James	Outperform
Mar-07-17	Initiated	Ladenburg Thalmann	Buy

View All

Leap Therapeutics Inc Stock (LPTX) Latest News

Here's Why Leap Therapeutics (LPTX) is Poised for a Turnaround After Losing -28.92% in 4 Weeks

Zacks Investment Research

Why FLJ Group Shares Are Trading Higher By Around 96%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Benzinga

Raymond James Maintains Outperform Rating for Leap Therapeutics: Here's What You Need To Know

Benzinga

Leap Therapeutics Inc Stock (LPTX) Financials Data

Leap Therapeutics Inc (LPTX) Revenue 2024

LPTX reported a revenue (TTM) of $1.50 million for the quarter ending December 31, 2021.

Leap Therapeutics Inc (LPTX) Net Income 2024

LPTX net income (TTM) was -$81.41 million for the quarter ending December 31, 2023, a -49.12% decrease year-over-year.

Leap Therapeutics Inc (LPTX) Cash Flow 2024

LPTX recorded a free cash flow (TTM) of -$43.75 million for the quarter ending December 31, 2023, a +10.79% increase year-over-year.

Leap Therapeutics Inc (LPTX) Earnings per Share 2024

LPTX earnings per share (TTM) was -$4.82 for the quarter ending December 31, 2023, a +0.21% growth year-over-year.

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.